Google-backed Isomorphic Labs has secured $2.1 billion in Series B funding, turning an earlier plan to raise more than $2 billion into one of the largest financing rounds for an AI-focused drug discovery company. The London-based company, which was spun out of Google DeepMind, plans to use the capital to expand its artificial intelligence drug-design platform, scale its global operations and advance its pipeline of potential medicines toward clinical development.
The funding highlights the growing investor interest in using AI not just to analyse biomedical information but to redesign how medicines are discovered and developed. Isomorphic Labs was founded in 2021 by DeepMind co-founder Demis Hassabis and is attempting to combine AI models, biological data and drug-design capabilities into an integrated platform. The company has also attracted pharmaceutical partnerships, giving its technology a route beyond research and toward actual drug development.
Isomorphic Labs Raises $2.1 Billion
Isomorphic Labs announced the $2.1 billion Series B round on May 12, 2026. The financing was led by Thrive Capital and included existing backers Alphabet and GV, along with new investors MGX, Temasek, CapitalG and the UK Sovereign AI Fund. The company did not disclose the valuation at which the round was completed.
The funding came after reports in May that Isomorphic Labs was in advanced discussions to raise more than $2 billion. At the time, Thrive Capital was expected to lead the round, with Alphabet also participating.
The company had previously raised $600 million in its first external financing round in 2025, also led by Thrive Capital. The latest round therefore represents a significant increase in the amount of capital being committed to the company’s AI-driven drug discovery strategy.
Isomorphic Labs Funding at a Glance
| Metric | Details |
|---|---|
| Latest funding | $2.1 billion Series B |
| Lead investor | Thrive Capital |
| Existing investors | Alphabet, GV |
| New investors | MGX, Temasek, CapitalG, UK Sovereign AI Fund |
| Earlier external funding | $600 million |
| Founded | 2021 |
| Origin | Google DeepMind spinout |
| Headquarters | London |
| Core focus | AI-powered drug discovery |
What Is Isomorphic Labs Building?
Isomorphic Labs is focused on applying AI to one of the most expensive and time-consuming parts of the pharmaceutical industry: discovering and designing potential new medicines.
Its technology includes the Isomorphic Labs Drug Design Engine, known as IsoDDE. The company describes the platform as an AI-first engine designed to support drug design and development across different therapeutic areas and drug modalities.
The basic proposition is that advanced AI models can help researchers understand biological mechanisms, identify potential drug targets and design molecules that could interact with those targets.
Traditional drug discovery can require years of laboratory research before a promising candidate reaches clinical trials. AI does not eliminate the biological and clinical testing required, but it can potentially improve parts of the early research process and allow scientists to evaluate a much larger number of possibilities.
That is the opportunity Isomorphic Labs is attempting to commercialise.
From AlphaFold to AI-Designed Medicines
The company’s origins are closely connected to DeepMind’s work in biology.
One of the best-known examples is AlphaFold, an AI system capable of predicting protein structures. Understanding protein structures is important because proteins play central roles in biological processes and can become targets for medicines.
Isomorphic Labs was created with a broader ambition: to use AI across the drug discovery process rather than focusing only on protein-structure prediction.
The company says it is building the data, AI models, software and physical infrastructure needed to take potential therapeutics from early-stage design toward patients in clinical settings.
Billions of Dollars Are Moving Into AI Drug Discovery
The size of Isomorphic Labs’ funding round reflects a wider shift in the AI investment landscape.
The first wave of generative AI investment was dominated by areas such as chatbots, enterprise software, computing infrastructure and AI models. Increasingly, investors are looking at scientific applications where AI could potentially create entirely new products.
Drug discovery is particularly attractive because successful medicines can generate significant economic value, while the pharmaceutical industry spends enormous amounts of money on research and development.
However, the sector also presents a much longer timeline than consumer AI.
An AI model can demonstrate its capabilities relatively quickly. A drug candidate has to pass laboratory testing, preclinical development, clinical trials and regulatory review before it can reach patients.
That makes the transition from AI research to commercial medicine one of the biggest tests facing companies such as Isomorphic Labs.
Pharmaceutical Partnerships Add Validation
Isomorphic Labs has already established partnerships with major pharmaceutical companies.
Its collaborations with Eli Lilly and Novartis have involved significant potential deal values, demonstrating that pharmaceutical companies are willing to work with AI-focused drug discovery businesses.
These partnerships are important because they provide access to pharmaceutical expertise, development capabilities and potential routes for AI-designed candidates to enter clinical development.
For investors, they also provide an indication that Isomorphic’s technology is being evaluated within real drug-development programmes rather than existing only as an experimental research project.
Clinical Trials Are the Next Major Test
One of the most important milestones for Isomorphic Labs is moving its drug candidates into human clinical trials.
Reuters reported that the company expected its first clinical trials by the end of 2026, after an earlier target of the end of 2025 was pushed back.
The delay illustrates the difficulty of applying AI to biology.
Predicting molecular behaviour or identifying potential drug candidates is only one part of the process. Researchers still have to establish whether a candidate is safe, effective and suitable for human use.
From AI Model to Medicine
AI models → Biological prediction → Drug design → Laboratory testing → Clinical trials → Regulatory approval → Patients
The biggest commercial test will therefore not simply be whether IsoDDE can generate promising molecules. It will be whether those molecules can successfully progress through the development process.
October Funding Talks Point to an Even Bigger Ambition
The $2.1 billion round may not be the final major financing milestone for Isomorphic Labs.
New Bloomberg reporting on October 8, 2026 said the company is in early discussions to raise additional funding at a valuation of at least $40 billion, with the valuation potentially reaching $50 billion. The talks have not closed and the terms could change.
If completed at those levels, such a financing would represent a dramatic increase in the company’s implied value only months after its $2.1 billion Series B.
It would also signal that investors increasingly view AI-powered drug discovery as a potentially major technology platform rather than simply another biotech application.
Why the Funding Matters for Alphabet
For Alphabet, Isomorphic Labs represents an important example of how the company’s AI research can be turned into businesses outside traditional internet products.
Alphabet has invested heavily in AI research through Google DeepMind. Isomorphic Labs provides a structure through which some of those advances can be applied commercially in healthcare.
The strategy also allows the company to attract external capital and pharmaceutical partners while maintaining a close relationship with Alphabet and Google’s AI ecosystem.
This creates a potential model for commercialising advanced AI research in highly specialised industries.
The Risks Behind the Opportunity
Despite the enormous investment, AI drug discovery remains a high-risk business.
Scientific predictions do not automatically translate into successful medicines. Clinical trials can fail because a drug is ineffective, unsafe or unable to demonstrate an acceptable benefit-risk profile.
The timeline is another challenge. Drug development can take many years, meaning investors may have to wait significantly longer for commercial returns than they would with conventional software businesses.
There is also intense competition. Numerous biotechnology companies, pharmaceutical companies and AI laboratories are developing their own systems for applying machine learning to biology and drug development.
The ability to consistently produce successful drug candidates will ultimately matter more than the size of any individual funding round.
The Bigger Picture
Isomorphic Labs’ $2.1 billion financing shows how the AI investment story is expanding from software into scientific discovery. The company is attempting to apply AI to one of the world’s most difficult problems: designing medicines that can eventually improve patient outcomes.
The more significant development may now be the company’s reported discussions around a potential new financing at a $40–50 billion valuation. If those talks progress, they would demonstrate how quickly investor expectations around AI-driven biotechnology have evolved.
For Alphabet, the opportunity is to turn breakthroughs in AI and computational biology into a new generation of healthcare businesses. For the pharmaceutical industry, the promise is faster and potentially more efficient drug discovery. But both will ultimately depend on whether AI-designed candidates can survive the demanding journey from computer models to successful clinical medicines.
Looking Ahead
The immediate focus for Isomorphic Labs will be advancing its therapeutic programmes and demonstrating that its AI drug-design technology can move beyond computational predictions into clinical development. The company’s expected clinical activity by the end of 2026 could become an important milestone for the broader AI drug discovery industry.
If the newly reported funding discussions eventually materialise at a $40–50 billion valuation, Isomorphic Labs could emerge as one of the world’s most highly valued AI-biotech companies. The bigger question, however, will remain whether its technology can consistently produce safe and effective medicines—a result that will ultimately determine the long-term commercial value of its AI-first approach.
Get the day’s top stories in your inbox
One concise email. No spam, unsubscribe anytime.
